Search Results - M.-L. Chretien

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IF... by C. Touzeau, A. Perrrot, C. Hulin, S. Manier, M. Macro, M.-L. Chretien, L. Karlin, O. Decaux, C. Jacquet, M. Tiab, X. Leleu, L. Planchce, H. Avet-Loiseau, P. Moreau

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE by A. Schavgoulidze, A. Perrot, T. Cazaubiel, X. Leleu, S. Manier, L. Buisson, S. Maheo, L. Do Souto Ferreira, R. Lannes, L. Pavageau, C. Hulin, J.-P. Marolleau, L. Voillat, K. Belhadj, M. Divoux, B. Slama, S. Brechignac, M. Macro, A.-M. Stoppa, L. Sanhes, F. Orsini-Piocelle, J. Fontan, M.-L. Chretien, H. Demarquette, M. Mohty, H. Avet-Loiseau, J. Corre

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: